论文部分内容阅读
对于雄激素撤除治疗后进展的前列腺癌尚无有效的治疗方法,二线内分泌治疗效果亦不明显。两个大型随机临床试验表明:以多西紫杉醇为基础的化疗能够延长患者的生存期,延缓疾病进展,这为多西紫杉醇联合一些新的生物制剂,巩固长期疗效提供了动力。随着肿瘤疫苗、单克隆抗体、骨靶向药物、反义寡核苷酸、抗血管生成药物和小分子酪氨酸激酶受体抑制剂等的出现,前列腺癌的治疗前景令人振奋。
There is no effective treatment for the progression of prostate cancer after androgen withdrawal therapy, and the second-line endocrine therapy is not effective either. Two large randomized clinical trials have shown that docetaxel-based chemotherapy prolongs patient survival and delays disease progression, providing the motivation for docetaxel in combination with several new biological agents to enhance long-term efficacy. With the emergence of tumor vaccines, monoclonal antibodies, bone-targeting drugs, antisense oligonucleotides, antiangiogenic drugs and small molecule tyrosine kinase receptor inhibitors, the prospect of prostate cancer is exciting.